Tumor lysis syndrome following trastuzumab for breast cancer: a case report and review of the literature.

Abstract

Tumor lysis syndrome, a complication of anticancer chemotherapy, results from rapid lysis of malignant cells. We report tumor lysis syndrome in a patient treated with trastuzumab for metastatic breast carcinoma. A 69-year-old woman was diagnosed with multiple liver metastases 1 month after mastectomy. As her liver functions had deteriorated, chemotherapeutic agents were contraindicated and she was treated with trastuzumab alone. On day 6 of the first course of trastuzumab, she developed tumor lysis syndrome. As her liver functions showed deterioration due to multiple hepatic metastases, hemodialysis was contraindicated. Acute renal failure worsened and she died 11 days after the administration of trastuzumab.

• Authors: Fumi Taira, Yoshiya Horimoto, Mitsue Saito
• Journal: Breast cancer (Tokyo, Japan) (Breast Cancer) Vol. 22 Issue 6 Pg. 664-8 (Nov 2015) ISSN: 1880-4233 [Electronic] Japan
• PMID: 23420376 (Publication Type: Case Reports, Journal Article, Review)

Chemical References

• Antineoplastic Agents
• Trastuzumab

Topics

• Aged
• Antineoplastic Agents (adverse effects)
• Breast Neoplasms (drug therapy, pathology)
• Female
• Humans
• Liver Neoplasms (secondary)
• Trastuzumab (adverse effects)
• Tumor Lysis Syndrome (etiology)